Skip to main content
Clinical Trials/NCT01280877
NCT01280877
Completed
Not Applicable

Multicenter Study of Paraorbital-Occipital Alternating Current Stimulation Therapy in Patients With Optic Neuropathy

University of Magdeburg4 sites in 1 country90 target enrollmentDecember 2010

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Optic Nerve Diseases
Sponsor
University of Magdeburg
Enrollment
90
Locations
4
Primary Endpoint
Detection accuracy (DA) change in percent over baseline within defective visual field
Status
Completed
Last Updated
9 years ago

Overview

Brief Summary

Aim is to validate that non-invasive brain stimulation can increase cortical excitability in the visual system. The investigators assess if transcranial alternating current stimulation (tACS) can improve visual field size in patients with optic nerve damage. Hypothesis: tACS would improve visual functions within the defective visual field (primary outcome measure).

Detailed Description

In addition, the correlation between the brain-derived neurotrophic factor (BDNF) or other plasticity markers are correlated to the improvement of the visual field after stimulation.

Registry
clinicaltrials.gov
Start Date
December 2010
End Date
February 2012
Last Updated
9 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Sponsor
University of Magdeburg
Responsible Party
Principal Investigator
Principal Investigator

Bernhard A. Sabel

Principle PI

University of Magdeburg

Eligibility Criteria

Inclusion Criteria

  • patients with optic nerve lesion
  • stable visual field defect with residual vision
  • lesion age at least 6 months
  • age at least 18 years
  • no completely blindness, residual vision still existent

Exclusion Criteria

  • electric or electronic implants, e.g. heart pacemaker
  • any metal artefacts in head and truncus
  • auto-immune diseases in acute stage
  • mental diseases, e.g. schizophrenia etc.
  • unstable diabetes, diabetes causing diabetic retinopathy
  • addiction
  • high blood pressure (max. 160/100 mmHg)
  • instable or high level of intraocular pressure (i.e. \> 27 mmHg)
  • retinitis pigmentosa
  • pathological nystagmus

Outcomes

Primary Outcomes

Detection accuracy (DA) change in percent over baseline within defective visual field

Time Frame: Baseline - 8 weeks after stimulation; First follow-up 2 days after treatment course; Second follow-up 8 weeks after treatment course

Central visual fields assessed with computer-based high-resolution perimetry (HRP). Based on such plots, areas of the visual field are characterized as intact, partially damaged or absolutely impaired (blind). Detection accuracy (DA) change in percent above baseline within defective visual field sectors is defined as the primary outcome criterion.

Secondary Outcomes

  • DA change in percent over baseline regarding the damage region of the tested visual field (computer-based high-resolution perimetry)(Baseline - 8 weeks after stimulation; First follow-up 2 days after treatment course; Second follow-up 8 weeks after treatment course)
  • EEG parameters(Baseline - 8 weeks after stimulation; First follow-up 2 days after treatment course; Second follow-up 8 weeks after treatment course)
  • Reaction time change in ms(Baseline - 8 weeks after stimulation; First follow-up 2 days after treatment course; Second follow-up 8 weeks after treatment course)
  • Visual acuity (VA)(Baseline - 8 weeks after stimulation; First follow-up 2 days after treatment course; Second follow-up 8 weeks after treatment course)
  • DA in static and kinetic conventional perimetry(Baseline - 8 weeks after stimulation; First follow-up 2 days after treatment course; Second follow-up 8 weeks after treatment course)

Study Sites (4)

Loading locations...

Similar Trials